NPPES file of Aug 9, 2026

Saleema Kherani-Ali, MD

Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician · Austin, TX

Saleema Kherani-Ali, MD is a uveitis and ocular inflammatory disease (ophthalmology) physician with a practice address in Austin, Texas, and NPI 1114487675, issued on Mar 21, 2019. Check the license (Texas V1513, as entered in NPPES) on the Texas Medical Board; the Medicare figures below come from public CMS files.

Record from CMS NPPES, file of Aug 9, 2026 · Medicare files 2024 · method · Verify with CMS →

NPPES recordNPPES file of Aug 9, 2026
1114487675
Name
Saleema Kherani-Ali
Credential
MD
Primary taxonomy
Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician 207WX0108X
License numbers
V1513 TX
036.165396 IL
Self-reported in NPPES; status is on the state search
Practice location
1601 Trinity St, Austin, TX 78712
Phone
(833) 882-2737
Enumerated
Mar 21, 2019
Record last updated
Jan 28, 2025
Medicare enrollment
Enrolled (PECOS I20240530001858); accepts Medicare assignment
Entity
Type 1 · individual
Public record from CMS NPPES (open it on the CMS NPI Registry). Enrollment, assignment, school and telehealth: CMS Doctors and Clinicians file, Aug 2026. A record is not a license: verify it with the state board.
Download card Updates feed

Also registered at 1601 Trinity St

A shared address usually means a shared clinic or building; it does not show who employs whom.

  1. Alyssa Aguirre, LICSWClinical Social Worker1306180989
  2. Jess Ambiee, LCSWClinical Social Worker1316454598
  3. Emily Andreasky, LMSWClinical Social Worker1770143703
  4. Nwabundo Anusim, M.DHematology & Oncology Physician1144504408
  5. Nicholas Barbaro, MDNeurological Surgery Physician1619925443
  6. Edward Bernacki, M.D.Endocrinology, Diabetes & Metabolism Physician1467418731

Verify Saleema Kherani-Ali in five checks

  1. 1IdentityNPI record in CMS NPPESNPI lookupConfirmed in NPPES
  2. 2LicenseActive license and public ordersTexas Medical Board
    Search for license V1513
    Check the board
  3. 3Other statesLicenses and actions elsewhereDocInfo (FSMB)Not checked
  4. 4ExclusionsMedicare and Medicaid bansHHS-OIG exclusion listNot checked
  5. 5CertificationBoard certificationABMS AOA NCCPA AANPNot checked
Open the Texas license search

PlainDoctor does not match the HHS-OIG exclusion list to individual records: most entries carry no NPI. Search the OIG exclusion list by name.

Is this page about you? You can ask us to correct, restrict or remove it: how.

61% fewer Medicare Part D claims than the average uveitis and ocular inflammatory disease (ophthalmology) physician in 2024

359 Medicare Part D claims for 95 beneficiaries, against an average of 916 among the 45 providers of this specialty who prescribed in Part D. Brand-name drugs were 35% of claims.

  1. Saleema Kherani-Ali359
  2. Specialty average916

Most prescribed

  1. Prednisolone Acetate54 claims
  2. Brimonidine Tartrate28 claims
  3. Difluprednate28 claims
  4. Erythromycin27 claims
  5. Dorzolamide Hcl26 claims
  6. Dorzolamide-Timolol25 claims

Source: CMS Medicare Part D Prescribers by Provider and Drug, 2024 (data.cms.gov). Part D covers prescriptions for Medicare patients only; drugs with fewer than 11 claims are not published.

Industry payments in 2024: $275.48

4 payments; by number, the most common kind was food and beverage; the largest payer was Abbvie Inc. The 42 providers of this specialty with any payment received $10,742.06 on average. Payments are reported by manufacturers, not by the provider, and are not a sign of wrongdoing.

  1. Saleema Kherani-Ali$275
  2. Specialty average$10,742

Source: CMS Open Payments, program year 2024 (openpaymentsdata.cms.gov); average among providers of this specialty with at least one payment.

Bills Medicare through one group practice

  1. The University OF Texas AT AustinAustin, TX

Source: CMS Doctors and Clinicians National Downloadable File (the group practices a clinician bills Medicare through) (data.cms.gov).

Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician providers in Texas

There are 4 uveitis and ocular inflammatory disease (ophthalmology) physician records in Texas.

The 3 uveitis and ocular inflammatory disease (ophthalmology) physician records with the nearest ZIP codes

  1. David Scales, M.D.San Antonio, TX 782401164412029
  2. Ashvini Reddy, M.D.San Antonio, TX 782311417102476
  3. Jennifer Cao, MDDallas, TX 753901861718942

Common questions

What is Saleema Kherani-Ali, MD's NPI number?

Saleema Kherani-Ali, MD's National Provider Identifier (NPI) is 1114487675, issued on Mar 21, 2019. An NPI identifies a provider in billing; it is not a license.

Where is Saleema Kherani-Ali, MD located?

The NPPES record lists a practice address at 1601 Trinity St, Austin, TX, 78712. Phone: (833) 882-2737. Providers update this record themselves, so call before visiting.

How can I verify Saleema Kherani-Ali, MD's license?

NPPES lists Texas license number V1513, as entered by the provider. Search the Texas Medical Board at https://profile.tmb.state.tx.us/Search.aspx. The NPPES record confirms identity only; the state search shows license status, expiration and public orders.

How much does Saleema Kherani-Ali, MD prescribe under Medicare Part D?

In 2024, Saleema Kherani-Ali, MD had 359 Medicare Part D claims for 95 beneficiaries; the average among uveitis and ocular inflammatory disease (ophthalmology) physician prescribers was 916. Part D covers Medicare prescriptions only.

Source: CMS National Plan and Provider Enumeration System (NPPES), file of Aug 9, 2026 (NPPES files on CMS.gov); NUCC Health Care Provider Taxonomy. Medicare files from data.cms.gov. An NPI identifies who bills; it is not a license.

Figures on PlainDoctor are read from the federal files each page names (CMS NPPES, Medicare Part D, MIPS, Open Payments; the HHS-OIG exclusion list only as counts) and from Census population estimates, with the file date shown beside them. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of Aug 9, 2026.